NCT05618613终止1 期
An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor-Positive, Progesterone Receptor-Positive, HER2-negative Advanced or Metastatic Breast Cancer (ELONA)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 4
- 试验地点
- 6
- 主要终点
- Determine the recommended Phase 2 dose (RP2D) of the combination of onapristone and elacestrant (Phase 1).
研究概览
简要总结
This is a multicenter, Phase 1b-2 study of elacestrant in combination with onapristone in patients with advanced/metastatic ER+/PgR+/HER2- breast cancer.
详细描述
This is a multicenter, phase 1b-2 trial. The phase 1b part of the trial is open label and aims to determine the recommended Phase 2 dose (RP2D) of onapristone and elacestrant when administered together. The Phase 2 part of the trial will evaluate the efficacy and safety of this combination in patients with ER+/PgR+/HER2- advanced/metastatic breast cancer after prior therapy with a CDK4/6 inhibitor.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Women or men aged ≥18 years, at the time of informed consent signature. Note: Pre- and peri-menopausal women must receive goserelin for at least one month prior to initiating trial therapy, during the trial, and for at least one month after end of trial therapy. Men must receive triptorelin for at least one month prior to initiating trial therapy, during the trial and for at least one month after end of trial therapy.
- •Histopathologically or cytologically confirmed ER+, PgR+, HER2-, breast cancer, per local laboratory, as per the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (Allison et al, 2020). Note: In the context of this trial, ER and PgR status will be considered positive if ≥10% of tumor cells demonstrate positive nuclear staining by immunohistochemistry.
- •At least one measurable lesion as per RECIST version 1.
- •Note: Patients with stable brain or subdural metastases are allowed if the patient has completed local therapy and has discontinued the use of corticosteroids for at least 4 weeks before starting treatment in this study. Any signs (e.g., radiologic) or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment.
- •Prior therapy with an aromatase inhibitor or fulvestrant + a CDK4/6 inhibitor in the metastatic setting or in the adjuvant setting if within 12 months of last dose of adjuvant therapy. Note: Prior therapy with everolimus is allowed.
- •ECOG performance status of 0 or
- •Patient has adequate bone marrow and organ function, as defined by the following laboratory values:
- •Absolute neutrophil count (ANC) ≥1.5 × 109/L,
- •Platelets ≥100 × 109/L,
- •Hemoglobin ≥9.0 g/dL,
- •Potassium, sodium, calcium (corrected for serum albumin), and magnesium CTCAE grade ≤1,
- •Cockcroft-Gault-based creatinine clearance ≥50 mL/min. Note: Creatinine clearance (male) = ([140-age in years] × weight in kg)/ ([serum creatinine in mg/dL] × 72) Creatinine clearance (female) = (0.85 × [140-age in years] × weight in kg)/ ([serum creatinine in mg/dL] × 72),
- •Serum albumin ≥3.0 g/dL (≥30 g/L),
- •In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 × ULN. If the patient has liver metastases, ALT and AST ≤5 × ULN,
- •Total serum bilirubin <1.5 × ULN except for patients with Gilbert's syndrome who may be included if the total serum bilirubin is ≤3.0 × ULN or direct bilirubin ≤1.5 × ULN.
排除标准
- •Active or newly diagnosed CNS metastases, including meningeal carcinomatosis.
- •Breast cancer treatment-naïve patients in the metastatic setting.
- •Prior therapy with elacestrant, onapristone, or chemotherapy in the metastatic setting.
- •Patient has a concurrent malignancy or history of invasive malignancy within 3 years of enrollment, with the exception of basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix that has completed curative therapy.
- •Uncontrolled significant active infections.
- •Patients with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection must have undetectable viral load during screening.
- •Patients known to be HIV+ are allowed as long as they have undetectable viral load at baseline.
- •Major surgery within 4 weeks before starting trial therapy.
- •Inability to take oral medication, or history of malabsorption syndrome or any other uncontrolled gastrointestinal condition.
- •Females of childbearing potential who:
- •Within 28 days before study entry, did not use a highly effective method of contraception.
- •Do not agree to use a highly effective method of contraception throughout the entire study period and for 28 days after trial therapy discontinuation.
- •Males who do not agree to abstain from donating sperm, or to use a highly effective method of contraception, during the course of the treatment period and for 28 days thereafter.
- •Known intolerance to either study drug or any of the excipients.
- •Patient is currently receiving or received any of the following medications prior to first dose of trial therapy:
- •Known strong or moderate inducers or inhibitors of cytochrome P450 (CYP) 3A4 within 14 days or 5 half-lives, whichever is shorter, (Refer to http://medicine.iupui.edu/clinpharm/ddis/),
- •Herbal preparations/medications within 7 days. These include, but are not limited to, St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng.
- •Investigational anti-cancer therapy with 21 days or 5 half-lives, whichever is shorter.
- •Vaccination, including but not limited to vaccination against COVID-19, during the 7 days prior to randomization.
- •Evidence of ongoing alcohol or drug abuse.
研究组 & 干预措施
Elacestrant / Onapristone
Experimental
Elacestrant and Onapristone combination
干预措施: Onapristone (Drug)
Elacestrant / Onapristone
Experimental
Elacestrant and Onapristone combination
干预措施: Elacestrant (Drug)
结局指标
主要结局
Determine the recommended Phase 2 dose (RP2D) of the combination of onapristone and elacestrant (Phase 1).
时间窗: 9 months
Evaluate the efficacy of elacestrant in combination with onapristone in terms of objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 (Phase 2).
时间窗: 1.5 years
Proportion of patients achieving a best overall response of confirmed partial or complete response (PR+CR).
Number of Participants With Dose-Limiting Toxicities (DLTs) During First Cycle
时间窗: First 28 days (Cycle 1)
DLTs were pre-specified toxicities occurring during Cycle 1 (28 days) and considered at least possibly related to study treatment, based on CTCAE criteria. Assessment of safety and tolerability to determine the recommended Phase 2 dose (RP2D). DLT defined as dose associated with \<33% of patients experiencing DLT (≤1 patient out of 6 DLT-evaluable patients).
Objective Response Rate (ORR)
时间窗: Assessed every 8 weeks until disease progression, up to approximately 6 months
ORR was defined as the proportion of patients achieving confirmed complete or partial response per RECIST v1.1; Phase 2 was not initiated, and no patients were enrolled.
次要结局
- Characterize the AEs of elacestrant in combination with onapristone.(21 months)
- Evaluate the maximum plasma concentration (Cmax) of elacestrant as well as onapristone and their metabolites (Phase 1).(9 months)
- Evaluate duration of response.(3 years)
- Evaluate progression-free survival.(3 years)
- Evaluate clinical benefit rate.(3 years)
- Evaluate overall survival.(3 years)
- Evaluate the trough concentration of elacestrant as well as onapristone and their metabolites (Phase 1).(9 months)
- Characterize the serious adverse events (SAEs) of elacestrant in combination with onapristone.(21 months)
- Characterize the safety in terms of changes in clinical laboratory values of elacestrant in combination with onapristone.(21 months)
- Characterize the safety in terms of changes in vital sign measurements of elacestrant in combination with onapristone.(21 months)
- Characterize the safety in terms of changes in ECG parameters of elacestrant in combination with onapristone.(21 months)
- Evaluate the area under the plasma concentration-time curve over the dosing interval of elacestrant as well as onapristone and their metabolites (Phase 1).(9 months)
- Evaluate the time of the maximum observed plasma concentration (Tmax) of elacestrant as well as onapristone and their metabolites (Phase 1).(9 months)
- Adverse Events (AEs)(From first dose until 30 days after last dose (up to 183 days))
- Serious Adverse Events (SAEs)(183 days)
- Evaluate the Maximum Plasma Concentration (Cmax) of Elacestrant as Well as Onapristone and Their Metabolites (Phase 1)(15 Days)
- Evaluate the Time of the Maximum Observed Plasma Concentration (Tmax) of Elacestrant as Well as Onapristone and Their Metabolites (Phase 1).(15 Days)
- Evaluate Duration of Response(From first documented CR/PR until progression or death, up to 183 days)
- Evaluate Clinical Benefit Rate(183 days)
- Evaluate Progression-free Survival(183 Days)
研究者
研究点 (6)
Loading locations...
相似试验
Unknown
1 期
Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate CancerAndrogen-independent Prostate CancerProstate CancerRecurrent Prostate CancerMetastatic Prostate CancerNCT02049190Arno Therapeutics75
招募中
2 期
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerAdvanced or Metastatic Breast CancerBRCA1 MutationBRCA2 MutationNCT06201234GBG Forschungs GmbH176
Unknown
1 期
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing CancersProgesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone TherapyNCT02052128Arno Therapeutics60
招募中
1 期
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerBreast NeoplasmsBrain NeoplasmsNeoplasms by SiteNeoplasmsBreast DiseasesCentral Nervous System NeoplasmsBrain DiseasesCentral Nervous System DiseasesNCT05386108Stemline Therapeutics, Inc.73
终止
2 期
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)ER-positive Breast CancerHER2-negative Breast CancerMetastatic CancerNCT04738292University of Wisconsin, Madison11